Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
出版年份 2022 全文链接
标题
Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-09-28
DOI
10.3389/fonc.2022.980214
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
- (2022) Josep M. Llovet et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
- (2022) Fei Yang et al. Frontiers in Immunology
- The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligand‐1 in advanced hepatocellular carcinoma patients
- (2022) Ma Xiaochen et al. Asia-Pacific Journal of Clinical Oncology
- A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma
- (2022) Satoshi Kobayashi et al. BMC CANCER
- Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor‐4 inhibition in hepatocellular carcinoma
- (2022) Norifumi Iseda et al. CANCER SCIENCE
- Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma
- (2022) Yan‐Jun Xiang et al. HEPATOLOGY RESEARCH
- Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma
- (2022) Kazuki Maesaka et al. HEPATOLOGY RESEARCH
- Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma
- (2022) Lei Wang et al. MEDICAL SCIENCE MONITOR
- Efficacy and safety of PD ‐1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study
- (2022) Junlin Yao et al. Cancer Medicine
- Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
- (2022) Mingyue Cai et al. Frontiers in Immunology
- Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma
- (2022) Qifan He et al. Frontiers in Immunology
- Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
- (2022) Shuping Qu et al. Frontiers in Oncology
- Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study
- (2022) Ruiqing Chen et al. Journal of Gastrointestinal Oncology
- Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study
- (2021) Shigeo Shimose et al. Cancers
- Lenvatinib for Hepatocellular Carcinoma: A Literature Review
- (2021) Takeshi Hatanaka et al. Pharmaceuticals
- Clinical outcomes and influencing factors of PD‑1/PD‑L1 in hepatocellular carcinoma (Review)
- (2021) Jiting Wang et al. Oncology Letters
- Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles
- (2021) Zhizhong Ren et al. Frontiers in Immunology
- Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
- (2021) Zhigang Fu et al. Hepatology International
- Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoembolization
- (2021) Kei Endo et al. HEPATOLOGY RESEARCH
- Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma
- (2021) Yuwa Ando et al. ONCOLOGY
- Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study
- (2021) Xiaoyan Ding et al. CANCER
- Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
- (2021) Richard S. Finn et al. CLINICAL CANCER RESEARCH
- Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC
- (2021) Chenhe Yi et al. HEPATOLOGY
- Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study
- (2021) Song Chen et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma
- (2021) Haijing Deng et al. Journal for ImmunoTherapy of Cancer
- Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
- (2021) Yusuke Adachi et al. CANCER RESEARCH
- Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
- (2021) Juanfang Liu et al. Frontiers in Pharmacology
- TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
- (2021) Biao Yang et al. Frontiers in Oncology
- First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials
- (2021) Wenfeng Liu et al. Frontiers in Oncology
- The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
- (2021) Fei Cao et al. Frontiers in Oncology
- Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
- (2021) Faiza Ahmed et al. World Journal of Gastrointestinal Oncology
- Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
- (2021) Jia-Yi Wu et al. Journal of Hepatocellular Carcinoma
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
- (2021) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma
- (2020) Haijing Deng et al. Liver Cancer
- Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
- (2020) TEIJI KUZUYA et al. ANTICANCER RESEARCH
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy
- (2020) Yan Zhao et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
- (2020) Shigeo Shimose et al. Oncology Letters
- Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization
- (2020) Naoshi Odagiri et al. Cancers
- Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
- (2020) Shigeo Shimose et al. Cancers
- Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
- (2020) Tomoko Aoki et al. Cancers
- Transarterial chemoembolization enhances programmed death 1 and programmed death‐ligand 1 expression in hepatocellular carcinoma
- (2020) Ahmed Montasser et al. HISTOPATHOLOGY
- Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
- (2019) Masatoshi Kudo WORLD JOURNAL OF GASTROENTEROLOGY
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
- (2019) Piao Li et al. JOURNAL OF IMMUNOLOGY
- A new ALBI‐based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma
- (2019) I‐Cheng Lee et al. LIVER INTERNATIONAL
- Hepatocellular carcinoma: Mechanisms of progression and immunotherapy
- (2019) Yu Jiang et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
- (2019) Masatoshi Kudo et al. Cancers
- REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
- (2019) Tatsuya Yamashita et al. JOURNAL OF GASTROENTEROLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
- (2018) Masahiro Matsuki et al. Cancer Medicine
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- Sorafenib: key lessons from over 10 years of experience
- (2018) Bernard Escudier et al. Expert Review of Anticancer Therapy
- Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients
- (2018) Atsushi Hiraoka et al. Liver Cancer
- The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
- (2017) David J. Pinato et al. JOURNAL OF HEPATOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- Peripheral Blood Regulatory T-Cell and Type 1 Helper T-Cell Population Decrease after Hepatic Artery Embolization
- (2016) Haruyuki Takaki et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- Increased Oxidative Stress and RUNX3 Hypermethylation in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma (HCC) and Induction of RUNX3 Hypermethylation by Reactive Oxygen Species in HCC Cells
- (2015) Poonsin Poungpairoj et al. Asian Pacific Journal of Cancer Prevention
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma
- (2015) Beom Kyung Kim et al. JOURNAL OF HEPATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now